Amicus Therapeutics (FOLD) Stock Price, News & Analysis

Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $7.40 to $7.54
• 50-Day Range: $5.64 to $7.61
• 52-Week Range: $5.51 to $12.65
• Volume: 1.34 million shs
• Average Volume: 3.86 million shs
• Market Capitalization: $2.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.22
• Consensus Rating: Moderate Buy

Amicus Therapeutics Stock Analysis - MarketRank™

Amicus Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 146th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Amicus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 186.67%

Earnings Growth

Earnings for Amicus Therapeutics are expected to grow by 186.67% in the coming year, from $0.15 to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amicus Therapeutics is -62.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amicus Therapeutics is -62.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amicus Therapeutics has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.19% of the float of Amicus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Amicus Therapeutics has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Amicus Therapeutics has recently decreased by 0.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amicus Therapeutics does not currently pay a dividend.

Dividend Growth

Amicus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.28

Percentage of Shares Shorted

7.19% of the float of Amicus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Amicus Therapeutics has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Amicus Therapeutics has recently decreased by 0.32%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.26

News Sentiment

Amicus Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Amicus Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

MarketBeat Follows

8 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amicus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Amicus Therapeutics is held by insiders.

FOLD Stock Analysis - Frequently Asked Questions

How have FOLD shares performed this year?

Amicus Therapeutics' stock was trading at $9.42 at the start of the year. Since then, FOLD stock has decreased by 20.3% and is now trading at $7.5050.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The company's quarterly revenue was up 34.0% on a year-over-year basis.
Read the conference call transcript.

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' top institutional investors include William Blair Investment Management LLC (4.76%), Vestal Point Capital LP (3.86%), State Street Corp (3.75%) and Perceptive Advisors LLC (2.40%). Insiders that own company stock include Bradley L Campbell, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout, Michael Raab and Margaret G Mcglynn.
View institutional ownership trends.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 8/26/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FOLD
• CIK: 1178879
• Web: www.amicusrx.com
• Phone: (215) 921-7600
• Fax: 609-662-2001
• Employees: 480
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Amicus Therapeutics: $16.22
• High Price Target: $22.00
• Low Price Target: $9.00
• Potential Upside/Downside: +117.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 49.63
• P/E Growth: N/A
• Net Income: -$56.11 million
• Net Margins: -6.67%
• Pretax Margin: -3.94%
• Return on Equity: -5.07%
• Return on Assets: -1.23%

Debt

• Debt-to-Equity Ratio: 1.92
• Current Ratio: 3.21
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $528.29 million
• Price / Sales: 4.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 11.45

Miscellaneous

• Outstanding Shares: 308,240,000
• Free Float: 301,458,000
• Market Cap: $2.29 billion
• Optionable: Optionable
• Beta: 0.53